問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Nephrology

更新時間:2023-09-19

黃道民
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

40Cases

2021-05-18 - 2023-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites

2026-07-01 - 2031-11-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2021-02-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-01-05 - 2029-11-11

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2024-03-15 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2024-09-30 - 2026-06-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-09-21 - 2026-06-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2026-02-01 - 2028-05-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2025-11-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-01-01 - 2023-06-30

Phase III

A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD
  • Condition/Disease

    Iron Deficiency Anemia With Non-Dialysis Dependent CKD

  • Test Drug

    PBF-1681

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

1 2 3 4